BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/8/2026 8:02:54 AM | Browse: 7 | Download: 0
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Tailoring therapy through response evaluation: A new era in the management of locally advanced rectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Peng Wang, Ding-Chao Liu, Wei-Ping Wang and Ke Hu |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
62476287 |
| National Key Research and Development Program of China, Ministry of Science and Technology of the People’s Republic of China |
2022YFC2402305 |
| National High Level Hospital Clinical Research Funding |
2025-PUMCH-A-028 |
|
| Corresponding Author |
Ke Hu, MD, Professor, Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing 100730, China. huke8000@126.com |
| Key Words |
Rectal cancer; Neoadjuvant therapy; Response evaluation; Tumor restaging; Minireview |
| Core Tip |
Neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for locally advanced rectal cancer. Accurate post-treatment evaluation and restaging are crucial to guide subsequent treatment and prognosis prediction. While conventional methods such as imaging and endoscopy are widely used, their application is hampered by several limitations. Emerging technologies such as detection of circulating tumor DNA, multi-omics, and artificial intelligence offer new perspectives for cancer restaging. Novel therapies such as total neoadjuvant therapy and watch-and wait strategies require enhanced precision in response assessment to optimize individualized therapeutic decisions and improve prognosis in patients with locally advanced rectal cancer. |
| Citation |
Wang P, Liu DC, Wang WP, Hu K. Tailoring therapy through response evaluation: A new era in the management of locally advanced rectal cancer. World J Gastrointest Oncol 2026; In press |
 |
Received |
|
2025-11-06 07:03 |
 |
Peer-Review Started |
|
2025-11-06 07:03 |
 |
First Decision by Editorial Office Director |
|
2025-12-02 07:35 |
 |
Return for Revision |
|
2025-12-02 07:35 |
 |
Revised |
|
2025-12-11 09:01 |
 |
Publication Fee Transferred |
|
2025-12-15 02:44 |
 |
Second Decision by Editor |
|
2026-01-08 02:47 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-01-08 08:02 |
 |
Articles in Press |
|
2026-01-08 08:02 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345